Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists - Wikidata - awgldk - TriplyDB

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

http://www.wikidata.org/entity/Q35124562

about

Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4 Highlight: BRCA1 and BRCA2 proteins in breast cancer Cyclin-dependent kinase inhibitor therapy for hematologic malignancies Finding the needle in the haystack: why high-throughput screening is good for your health.Recent Developments in Peptide-Based Nucleic Acid Delivery Drugging the addict: non-oncogene addiction as a target for cancer therapy Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics E2F-3B is a physiological target of cyclin A REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors.Tossing monkey wrenches into the clock: new ways of treating cancer.Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032 Anticancer drug targets: cell cycle and checkpoint control.Apoptosis in cancer.S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells.CNS delivery via adsorptive transcytosis.Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1.Tailoring to RB: tumour suppressor status and therapeutic response.Cell cycle and apoptosis.Cyclin-dependent kinase inhibitors: novel anticancer agents.Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status.Combinatorial targeting and discovery of ligand-receptors in organelles of mammalian cells Selective inhibition of calcineurin-NFAT signaling by blocking protein-protein interaction with small organic molecules.Inhibition of Siah ubiquitin ligase function.Prevention of radiation-induced salivary gland dysfunction utilizing a CDK inhibitor in a mouse model T antigens of simian virus 40: molecular chaperones for viral replication and tumorigenesis Targeting the cell cycle for cancer therapy.Defects in G1-S cell cycle control in head and neck cancer: a review.Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer.Polarized distribution of IQGAP proteins in gastric parietal cells and their roles in regulated epithelial cell secretion.Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity CDK inhibitors in clinical development for the treatment of cancer.Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.Efficient soluble expression of active recombinant human cyclin A2 mediated by E. coli molecular chaperones.Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.The A-type cyclins and the meiotic cell cycle in mammalian male germ cells.Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle.Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells.Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization

P2860

Q24294703-24DE0407-B855-4B6D-97B6-6F2BDE3C0075 Q24307401-BEBB8312-A0F4-4837-A9CE-A705C0AC523B Q24561485-4628317A-12DF-4216-A616-C0B7BA153ECC Q24802613-54CC9B08-C033-479E-A802-AA2117CD5945 Q27487857-3646213C-2F4B-42F1-8182-706BDE42C249 Q28079559-4037CC23-C93A-4236-851A-B74713730EA7 Q28254233-74BD72E0-9230-4D80-AE80-CCE4597CB353 Q28592030-DC212A11-00B7-47D1-88CA-C1CB7642D32A Q30357531-6E1E4D35-FBC4-4480-BFD8-BF442DD2B243 Q33592190-675DF5D8-410B-43E0-8AD6-D614EC8F5C58 Q33642396-C8B0296B-3D35-4205-A928-76FC69FAA638 Q33801116-D6AD9DAB-E591-4054-846D-9C0B4B250DD4 Q33846227-A77D1A68-D777-4FD2-8E7E-73C2B2222329 Q33941051-1995EE63-27A7-4E3E-B0E5-9365FDA45718 Q34013526-F251A330-987B-4D93-BA54-0E72915725C4 Q34031684-1202ED87-20A5-4CD3-95B7-98D90B0CD803 Q34040108-44A40D93-7460-4C8E-A580-34F85E93295B Q34045686-226CC3DC-3318-4780-B900-280E928D2381 Q34075028-FAABEA99-3106-4D27-A3D2-A4B31E0FBCF3 Q34090992-1355DF21-DA1B-46B8-980B-70CDA2ECF837 Q34236236-14498D05-215D-4883-B220-F5C7A769AFEA Q34335785-8E0DCA4B-EC25-429F-9263-D1CB265DFEE1 Q34400571-CB44E425-73AE-4296-9968-9FBAA4723409 Q34510942-E8F8BA2B-E541-4216-92F6-5B7082F2E8FC Q34662543-50AAF3FA-E398-4807-94DF-07FD39ECD448 Q34728354-EF3EF9F6-D9C1-4183-A6BF-BB71CB2006F0 Q34733424-20C08076-B935-44E9-9D3E-C102125F0818 Q34807961-7FFDE70B-2A28-49C0-88E6-680A026E2ECB Q34813680-F11FD1BD-FED3-4A7C-AF8F-87405EC7E40C Q35100606-FE89B6D6-34A6-4046-B44B-A3A8F00D3D6C Q35143997-1A99E153-66B2-4CE2-8254-232AB52E6AB6 Q35176113-DF591F39-1C3D-40C4-9E1C-F25DF0DDFFCB Q35685158-06B78C24-B426-4CEE-BFBA-06578FBDB2D6 Q35837170-3FD49B47-C81C-492C-8ABA-72463658ACC0 Q35843959-304A5C1C-B2B7-4F30-B9A6-F751C93EFAAB Q36118431-5FD8F0C9-92E0-4762-BB4B-D5EFAAD8CD24 Q36120794-664800A9-4FF3-4DC0-A5AA-E6A63E5EE73D Q36187896-2D6B6D29-2D6B-4C6F-8E8E-DA0B156CA30B Q36247797-E3D8EE9C-D5EB-4044-B886-C34623385B00 Q36347006-B0C61FF1-DE83-47A3-B361-4C6DF01BC2FC

P2860

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

http://www.wikidata.org/entity/Q35124562

description

1999 nî lūn-bûn

@nan

1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

@ast

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

@en

type

label

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

@ast

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

@en

prefLabel

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

@ast

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

@en

P1433

Q35124562-0A997A21-B5CD-4A8D-B46A-51FDFAE57F1E

P1476

Q35124562-BC7482A8-C7D1-49FB-8183-450E9FFBCFBA

P2093

Q35124562-0839F9D6-45F1-45C3-BA47-6A3F474F5B14

Q35124562-096DF223-A68C-4B7B-8120-6077B195AA47

Q35124562-36B14854-9484-4307-B871-79A25110D84C

Q35124562-41BA3FB3-A365-4FEF-BFE3-BDE468E13D4F

Q35124562-85746942-63E2-409C-A2FE-4A11440B0955

Q35124562-A3B7C30E-D14A-4E61-991E-6163EC7A4C38

Q35124562-BE9DA92D-A060-4FBC-95CC-2B0F738F45EC

Q35124562-E94CD91B-2EC9-4B0B-93E7-94C1FE0B0E74

Q35124562-FFC984E2-E365-4A29-88FE-E8D402C0742C

P2860

Q35124562-05910898-CB5B-4EDF-897D-AED2DBB56393

Q35124562-07E2F8AA-6F2C-4452-9486-6FC9A66F7041

Q35124562-0FCE226E-F860-4527-AFC1-6961C49C3D90

Q35124562-2ED5C6DF-584A-4069-BC0C-95C682649A38

Q35124562-339F6767-3073-43B4-A568-C4FB584FC7FD

Q35124562-4C1516D3-ABA1-479D-A93C-832638BE5079

Q35124562-58353B71-0536-437B-9217-9460F1EE4D2B

Q35124562-5F2A9669-29A7-4FBE-97EF-4F666B24A03C

Q35124562-61013294-374B-4C00-B7EE-2DF49ABAF0EB

Q35124562-65C4A91E-5DC3-46CD-98CD-051BE17142CD

P304

Q35124562-D1B1564B-C37D-44EA-924B-316A5ADDC939

P31

Q35124562-342F6503-42AD-4311-A4B3-87324DDB5E87

P356

Q35124562-B5AEA81D-6E71-4BE8-ACB3-10DE74C2A549

P407

Q35124562-1850F76B-8517-433E-9CAE-B9509F6CBA69

P433

Q35124562-4725813F-E60E-4161-822E-C262A27105CC

P478

Q35124562-E3B9C04A-18FE-4B8F-AA76-F48072388C26

P577

Q35124562-CBF16E16-FC79-41F6-8B2F-877EE18D2089

P5875

Q35124562-19AC5E54-27BA-4BC4-BA6C-C5461B1637D8

P698

Q35124562-7CEACD7F-9B35-40B7-8E25-BCB8CEC78D8D

P932

Q35124562-47F09542-B7DD-4ADF-9C07-7F5CF6F62200

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

@en

P2093

K Baker

http://www.w3.org/2001/XMLSchema#string

K W Bair

http://www.w3.org/2001/XMLSchema#string

L Jiang

http://www.w3.org/2001/XMLSchema#string

M S Martin

http://www.w3.org/2001/XMLSchema#string

P D Adams

http://www.w3.org/2001/XMLSchema#string

S K Sharma

http://www.w3.org/2001/XMLSchema#string

T M Ramsey

http://www.w3.org/2001/XMLSchema#string

W G Kaelin

http://www.w3.org/2001/XMLSchema#string

Y N Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclin-binding motifs are essential for the function of p21CIP1

The retinoblastoma protein binds to a family of E2F transcription factors

Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex

Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation

Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A

Differential regulation of E2F transactivation by cyclin/cdk2 complexes

Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase

Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line

Cancer cell cycles

Expression of transcription factor E2F1 induces quiescent cells to enter S phase.

P304

4325-4329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.96.8.4325

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

1999-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13098481

http://www.w3.org/2001/XMLSchema#string

P698

10200261

http://www.w3.org/2001/XMLSchema#string

P932

16331

http://www.w3.org/2001/XMLSchema#string